Status:
COMPLETED
Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension
Lead Sponsor:
University of Vigo
Collaborating Sponsors:
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime...
Detailed Description
Several attributes of the cardiovascular system, including blood pressure (BP) and heart rate (HR), are characterized by predictable changes during the 24 hours for the most part in synchrony with the...
Eligibility Criteria
Inclusion
- Essential hypertension
Exclusion
- Severe hypertension.
- Secondary hypertension.
- Grade III/IV hypertensive retinopathy.
- Type 1 diabetes.
- Cerebrovascular or cardiovascular event during the last 12 months prior to inclusion.
- Pregnant or lactating females.
- History of malignancy within the past five years.
- Shift workers.
- Obstructive sleep apnea.
- Use of disallowed concomitant medication.
- Intolerant to ABPM.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00473174
Start Date
March 1 2007
End Date
December 1 2008
Last Update
September 2 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain, 15701